DRC announces plans to use second Ebola vaccine
Health authorities in the Democratic Republic of Congo are planning to use a second vaccine to treat the Ebola virus.
List view / Grid view
Health authorities in the Democratic Republic of Congo are planning to use a second vaccine to treat the Ebola virus.
A treatment for anaemia associated with chronic kidney disease in dialysis patients has been approved in Japan.
Darmerica LLC is voluntarily recalling two lots of quinacrine dihydrochloride due to a label mix-up.
The government of an Indian province and a US company have teamed together in an initiative to deliver medications to remote regions using drones, which should begin next year.
A new report has shown that trial evidence alone is not enough when approving new cancer drugs and that an assessment of that evidence is also needed.
A Biologics License Application and priority review has been approved by the FDA for an investigational Ebola vaccine.
Lanadelumab, a preventive treatment for hereditary angioedema, has been recommended as a cost-effective use of NHS resources.
Pharmaceutical Manufacturing Research Services has filed a lawsuit against the FDA after it rejected its application for opioids with updated labelling and appearance, meant to discourage misuse.
A new initiative has already collaboratively reviewed applications for two oncology drugs, allowing for simultaneous decisions in three countries.
The UK Medicine and Healthcare products Regulatory Agency has released a revision to its standards for ensuring high quality of biologic products.
Orphan Drug Designation has been given to bispecific antibody candidate, GBR 1342, for the treatment of multiple myeloma.
Cosentyx®, a treatment for an inflammatory disease has met its primary endpoints in patients during a Phase III trial.
The market for containment facilities and containment manufacturing will increase in the future, due to a growing demand for oncology treatments.
Farxiga (dapagliflozin) has been given Fast Track designation by the FDA to reduce the risk of cardiovascular death.
New vaccine patch has showed no negative side effects and could lead to a replacement of needle-based vaccination methods.